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Abstract
BACKGROUND: The prognostic value of myocardial perfusion 
scintigraphy (MPS) continues to attract interest and provoke dis-
cussions. This study was an attempt to investigate the methods.
OBjeCtive: Determination of the prognostic value of MPS 
for patients suspected of and diagnosed with coronary artery 
disease (CAD).
MAteRiAL AND MetHODS: The study group included 215 
patients, 134 males and 81 females, aged 21–66, mean age 
48. Tc-99m-MIBI myocardial perfusion scintigraphy was per-
formed and information concerning the diagnosis, aim of the 
examination, past coronary episodes, clinical condition, dura-
tion and type of complaints, concomitant diseases, test results, 
revascularisation procedures and pharmacological treatment 
was gathered. Further history of the patients was monitored 
throughout the observation period of 52 months on average. 
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The patients were divided into the following two groups: Group 
I — suspected coronary artery disease: 124 patients aged 21–65, 
59 males and 65 females; Group II — diagnosed coronary artery 
disease: 91 patients aged 31–66, 75 males and 16 females 
diagnosed with CAD, including 39 s/p myocardial infarct, 31 
s/p infarct and revascularisation, 21 s/p revascularisation. The 
probability of CAD was calculated using the Diamond method 
for the patients suspected of CAD. The obtained results were 
examined in a statistical analysis.
ReSULtS: Normal MPS results were obtained for 94/124 pa-
tients suspected of CAD, 15/91 patients diagnosed with CAD, 
64/81 females and 45/134 males. In Group I, apart from patho-
logical MPS results, reversible ischemia was determined in as 
many as 27/30 patients, and only 17/91 patients in Group II. No 
patients with normal MPS results suffered major cardiac events, 
only one of them underwent revascularisation. Major cardiac 
events occurred in the case of patients with pathological MPS 
results: Group I — 2 myocardial infarcts and 2 cardiac deaths, 
Group II — 3 infarcts and 10 cardiac deaths. Minor cardiac 
events, apart from one case, were also only observed in the 
case of patients with pathological MPS results: Group I — 10 
revascularisations and one case of unstable CAD, Group II 
— 12 revascularisations and 7 cases of unstable CAD. Patients 
with normal MPS results and stenosis in coronary angioraphy 
suffered no cardiac events. Cardiac events occur mostly in the 
group with a medium and high risk of CAD and in the case of 
patients diagnosed with CAD.
CONCLUSiONS: 1. Normal MPS results for patients suspected 
of or diagnosed with CAD: s/p infarct and/or CABG prognos-
ticate a mild course of the disease, without or with a minimal 
number of cardiac events, also in a longer observation period. 
2. Pathological MPS results clearly imply a greater risk of cardiac 
events, and the number of events increases with the greater 
probability of CAD and with the patient’s age. 3. Normal MPS 
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results, even with significant stenosis in coronary angiography, 
prognosticate a low risk of cardiac events.
Key words: myocardial perfusion scintigraphy, prognostic 
value
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Introduction
Usually coronary artery disease (CAD) can be diagnosed 
based on the results of non-invasive diagnostic methods. They 
help determine the coronary flow reserve, myocardial haemody-
namics and possibly define patient’s eligibility for an invasive dia-
gnostic procedure, mostly coronary angioraphy. Not only are they 
helpful in diagnosing and choosing the best treatment, but they 
also have prognostic value. A prognosis means the anticipated 
course of disease and the prospect of specific events. In the case 
of CAD, myocardial infarct or cardiac death, i.e. so-called major 
cardiac events, revascularisation or emergence of unstable CAD, 
i.e. so-called minor cardiac events, are mostly taken into consid-
eration. The applied diagnostic procedures can have a different 
prognostic value, also referred to as a predictive value of a test, 
in assessing the probability of an event.
The diagnostic procedures applied in the case of CAD pa-
tients are frequently complementary methods. The objective is to 
select a method or methods most appropriate in a given clinical 
situation. Myocardial perfusion scintigraphy (MPS) is a procedure 
which enables assessing the impairment of the coronary circula-
tion. Patients with indications for MPS can be divided into several 
groups: patients suspected of CAD, those diagnosed with stable 
CAD, patients status post such cardiac events as infarct and/or 
revascularisation, status ante revascularisation for the assessment 
of myocardial viability, patients with an acute coronary episode 
after thrombolytic therapy. In the recent years, the prognosis and 
assessment of the risk of cardiac events was considered another 
indication for MPS [1]. The high prognostic value of MPS was con-
firmed in a number of papers, regardless of the applied radio-
pharmaceuticals and stress protocols. The risk of major cardiac 
events increases in proportion to the number of segments with 
reversible or persistent ischemia [2–4]. The aim of this paper 
is to determine the prognostic value of Tc-99m-MIBI MPS for pa-
tients suspected of and diagnosed with coronary artery disease.
Material and methods
The study group included 215 patients, 134 males and 81 fe-
males, aged 21–66, mean age 48 ± 9 (SD), status post myocardial 
perfusion scintigraphy. All the patients provided information on 
their further history during the observation period of 36-86 months, 
mean duration 52 months. 
The patients were divided into the following two groups:
 — Group I — suspected coronary artery disease — 124 pa-
tients aged 21–65, mean age 47 ± 10 (SD), 59 males and 65 
females non-diagnosed with myocardial infarct and without 
any significant coronary lesions in coronary angiography; 103 
patients referred for MPS to determine indications for coronary 
angiography, 21 patients with persistent typical coronary com-
plaints and lack of any clinically significant coronary lesions in 
coronary angiography;
 — Group II — diagnosed coronary artery disease — 91 pa-
tients aged 31–66, mean age 50±9 (SD), 75 males and 16 
females diagnosed with CAD, including 39 patients s/p myo-
cardial infarct (determined based on typical clinical symptoms, 
ECG results and biochemical tests), 31 patients s/p myocardial 
infarct and revascularisation, 21 patients s/p revascularisation; 
a total of 70 patients were observed to have had an infarct: 18 
patients within up to half a year, 16 patients within more than 
six months to one year, and 36 patients within more than one 
year prior to the examination. Revascularisation was performed 
in a total of 52 patients, in 38 within up to one year, and in 14 
within more than one year prior to MPS. The above groups are 
characterised in Table 1.
For all the patients suspected of CAD, without infarct, revas-
cularisation and with normal coronary angiography results, the 
probability of CAD was calculated using the Diamond method, i.e. 
based on their age, sex and type of complaints. The patients were 
divided according to the results into groups with a low, medium 
and high risk of CAD: from 0 to 0.30 — low risk, 0.31 to 0.70 — me-
dium risk, more than 0.71 — high risk of coronary artery disease.
MPS was performed according to a two-day protocol. Scin-
tigraphy at rest involved IV administration of 700–800 MBq of 
Tc-99m-MIBI, SPECT images were acquired within 40–60 mi-
nutes after the administration of the radiopharmaceutical. Stress test 
was performed according to the Bruce protocol, where physical 
stress test was combined with IV administration of dipyridamole. The 
physical stress test was terminated when patients achieved at least 
85% of the heart rate limit or positive test features were observed. 
One minute prior to the anticipated termination, 700–800 MBq of 
Tc-99m-MIBI was administered intravenously. Post-stress SPECT 
images were acquired, similarly as during the test at rest, within 
40–60 minutes after the administration of the radiopharmaceutical. 
All the examinations were registered with a Picker gamma camera, 
Dyna Pro SX-300. Tomographic profiles were reconstructed by back 
projection using first Metz filter, and then median filter. A series of 
images along the cardiac short axis were obtained — frontal, hori-
zontal and sagittal images as well as two series of long-axis images. 
Information about the patients’ history in the defined obser-
vation period, i.e. at least 36 months after the MPS examination, 
was obtained retrospectively based on: questionnaire responses, 
hospital documentation, coronary angiography results, personal or 
telephone interviews, review of the whole group for deaths in the 
civil registry office. The questionnaire included questions about the 
further course of the disease, additional examinations, revasculari-
sation procedures, medication, current complaints, hospitalisation, 
cardiac events. Cardiac events were divided into: “major” events, 
such as myocardial infarct and cardiac death, and “minor” events, 
such as revascularisation due to coronary complaints (CABG or 
PTCA) and unstable coronary artery disease (intensified coronary 
complaints with recurring hospitalisation periods). Cardiac death 
was defined as death for the major reason of suspected or dia-
gnosed myocardial infarct, life-threatening arrhythmia, pulmo-
nary oedema or suspected cardiac death with no other causes 
diagnosed. The observation period was terminated at the time of 
an infarct, death or revascularisation. 
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The assessment of to what extent the specific factors have 
contributed to the cardiac event was carried out based on the 
multivariate Cox proportional hazards model. The survival analy-
sis was based on the Kaplan-Meier test. The comparison of the 
survival rate in each class was based on the log-rank test. The statis-
tical analysis was carried out with the level of significance p < 0.05.
Results
The involvement of one segment was observed in 27 (12%) 
patients, of two segments in 24 (11%) patients, of three seg-
ments in 21 (10%) patients, of four segments in 19 (9%) patients, 
and of more than four segments in 15 (7%) patients. Reversible 
ischemia of one segment was determined in 31 (14%) patients, 
of two segments in 27 (12%) patients, of three segments in 20 
(10%) patients, and of four segments in 6 (3%) patients. Irreversible 
ischemia of one segment was detected in 24 (11%) patients, of 
two segments in 22 (10%) patients, of three segments in 11 (5%) 
patients, and of four segments in 5 (2%) patients. The results ac-
cording to the number of segments with irreversible and rever-
sible ischemia, and the total number of the involved segments, 
irrespective of the pathology, are shown in Figure 1 for Group I and 
in Figure 2 for Group II. Group I included a significant number 
of patients with reversible ischemia which can be attributed to 
the type of patients — these are patients suspected of coronary 
artery disease, without any past coronary episodes determined 
in the interview, prior to any revascularisation treatment. On the 
other hand, Group II was dominated by patients with irreversible 
ischemia and there were also more patients with a greater num-
ber of involved segments. In Group I, there was only one patient 
with more than 4 segments involved, while in Group II, there were 
fourteen such patients.
The type of applied treatment, complaints and cardiac 
events reported in Group I, broken down into normal and patho-
logical MPS results, are shown in Table 2. The average observa-
tion period for the group with normal MPS results was 58 months. 
In the case of the group with pathological MPS results, the 
observation period was shorter - only 38 months. Coronary 
angiography was performed for a similar number of patients in 
table 1. Description of patients based on the interviews (n = 215)
  Group I. Suspected CAD Group II. Diagnosed CAD Total
Number of patients 124 (100%) 91 (100%) 215 (100%)
Male 59 (47%) 75 (82%) 134 (62%)
Female 65 (53%) 16 (18%) 81 (34%)
Age 47 ± 9 (SD) 50 ± 9 (SD) 48 ± 9 (SD)
Typical ischaemic symptoms 74 (60%) 54 (61%) 128 (59%)
Atypical ischaemic symptoms 42 (34%) 19 (20%) 61 (28%)
Duration of symptoms < 1 month 12 (10%) 5 (5%) 17 (8%)
Duration of symptom > 1 month < 1 year 48 (38%) 36 (39%) 84 (39%)
Duration of symptom > 1 year 30 (24%) 11 (12%) 41 (19%)
Coexistent diseases1 60 (49%) 55 (59%) 115 (53%)
Normal ECG result 50 (40%) 12 (13%) 62 (29%)
Abnormal ECG result2 72 (58%) 76 (85%) 148 (69%)
Normal Holter record 38 (31%) 15 (16%) 53 (25%)
Abnormal Holter record 40 (33%) 11 (12%) 51 (24%)
Normal stress test in ECG 25 (20%) 21 (22%) 46 (21%)
Abnormal stress test in ECG 56 (44%) 31 (34%) 87 (40%)
Normal rest ultrasound 82 (66%) 35 (39%) 117 (54%)
Abnormal rest ultrasound 7 (6%) 39 (42%) 46 (21%)
Pharmacological treatment3 59 (48%) 52 (57%) 111 (52%)
1 — hypertension, diabetes, hyperlipidaemia; 2 — past infarct, ischemic features, extrasystoles, repolarisation disorders, atrial fibrillation, right or left bundle branch block, Wolff- 
-Parkinson-White syndrome (WPW); 3 — angiotensin converting enzyme inhibitors, beta-blockers, nitrates
Figure 1. Number of segments with a cicatrix and/or reversible is-
chemia within the left-ventricular muscle in the case of patients with 
pathological MPS results in Group I
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both subgroups — 27/124 patients. Some patients were ad-
ministered pharmacological treatment, 58 (47%) patients with 
normal MPS results and 20 (16%) patients with pathological 
MPS results. Pharmacological treatment is detailed in Table 2. 
56 (45%) patients with normal MPS results and only 14 (11%) 
patients with pathological MPS results reported both typical and 
atypical coronary complaints. Only one patient with normal MPS 
results was observed to suffer a revascularisation-like cardiac 
event. No “major” events , i.e. myocardial infarct or cardiac death, 
were observed. However, in the case of patients with pathological 
MPS results, 2 of them had myocardial infarct, 2 suffered car-
diac death, 10 underwent revascularisation, and 1 had unstable 
coronary artery disease.
Table 3 specifies the type of applied treatment, cardiac 
events and complaints reported in Group II, broken down into 
normal and pathological MPS results. The average observation 
period for the group with normal MPS results was 56 months. For 
the group with pathological MPS results a slightly shorter (although 
the difference was not statistically significant) observation period 
of 50 months was applied. Coronary angiography was only per-
formed in 4 patients with normal MPS results. Clinically significant 
coronary stenosis was observed in 18 out of 19 coronary angiog-
raphy procedures performed in patients with pathological MPS 
results. Pharmacological treatment was applied for the majority 
of patients with pathological MPS results, as shown in Table 3. 
Even with the treatment, both typical and atypical coronary com-
plaints were observed. Except for two patients from the group 
with normal MPS results, who underwent revascularisation, no 
other cardiac events were observed in this group. In the group 
with pathological MPS results, 3 patients had myocardial infarct, 
10 suffered cardiac death, 12 underwent revascularisation, and 
7 had unstable coronary artery disease. 
Figure 2. Number of segments with a cicatrix and/or reversible is-
chemia within the left-ventricular muscle in the case of patients with 
pathological MPS results in Group II
table 2. treatment, complaints and cardiac events during the observation period in the group of patients suspected of CAD (Group i) 
according to MPS results table 2. treatment, complaints and cardiac events during the observation period in the group of patients 
suspected of CAD (Group i) according to MPS results
  Normal MPS Abnormal MPS Total
No of patients 94 (76%) 30 (24%) 124 (100%)
Time of follow up in months 58 ±14 (SD) 38 ± 26 (SD) 53± 20 (SD)
Coronarography after MPS 13 (10%) 14 (11%) 27 (22%)
Coronarography result    
Normal 12 (10%) 5 (4%) 17 (14%)
Abnormal 1 (1%) 9 (7%) 10 (7%)
Drugs 58 (47%) 20 (16%) 78 (63%)
Drugs group    
ACE inhibitors 18 (15%) 6 (5%) 24 (20%)
Beta-blockers 30 (25%) 11 (9%) 41 (34%)
Nitrates 37 (31%) 17 (14%) 54 (55%)
Symptoms 56 (45%) 14 (11%) 70 (56%)
Type of symptoms    
Typical ischaemic 26 (21%) 11 (9%) 37 (30%)
Atypical 30 (24%) 3 (2%) 33 (265)
Events in observation    
Infarct 0 2 (2%) 2 (2%)
Interventional treatement 1 (1%) 10 (8%) 11 (9%)
Instable coronary disease 0 1 (1%) 1 (1%)
Death 0 2 (2%) 2 (2%)
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The group of patients who suffered major cardiac events (myo-
cardial infarct or death) is especially interesting. This group 
included 4 females and 13 males. 2 female patients suffered 
cardiac death and 2 myocardial infarct. Both female patients were 
36 and 41 years old respectively at the time of death. One of 
them died within 2 months after MPS due to complications in 
the post-revascularisation perioperative period, and the other 
one within 32 months after MPS. Concomitant diseases, such 
as diabetes and/or arterial hypertension, were determined in 10 
patients. Four patients reported no complaints, the other pa-
tients had coronary or atypical complaints. Indications for MPS 
were diverse: post-CABG follow-up examination in the case of 
3 patients, post-CABG and post-myocardial infarct follow-up 
examination — 4 patients, post-infarct follow-up examination 
— 6 patients, post-coronary angiography follow-up examination 
— 2 patients, and pre-coronary angiography examination 
— 2 patients. It should be pointed out that as a result of MPS 8 pa-
tients were found to suffer from reversible ischemia, 7 patients were 
found to have a cicatrix and related reversible ischemia, and 
2 patients — a cicatrix within the left-ventricular muscle. In the case 
of these patients the number of segments involved was 3 or more. 
For patients from Group I, i.e. patients suspected of CAD, 
without documented coronary episodes, the probability of CAD 
was calculated using the Diamond method at the interview stage. 
Figure 3 shows the occurrence of cardiac events for the groups of 
patients with a low risk of CAD from 0 to 30%, a medium risk from 
31 to 70% and a high risk from 71 to 99%. These groups were 
also divided according to normal and pathological MPS results. 
The risk level for patients from Group II, i.e. patients diagnosed 
with CAD, was defined as 100%. As shown in the figure, cardiac 
events occur mostly in the groups with a medium and high risk 
of CAD and in the group of patients diagnosed with CAD. Apart 
from one revascularisation, they were observed in the case of 
patients with pathological MPS results. Infarcts and deaths oc-
curred relatively evenly during the entire observation period, while 
table 3. treatment, complaints and cardiac events during the observation period in the group of patients diagnosed with CAD (Group ii) 
according to MPS results (n = 91)
  Normal MPS Abnormal MPS Total
No of patients 15 (16%) 76 (84%) 91 (100%)
Time of follow up in months 56 ± 17 (SD) 50 ± 22 (SD) 51± 21 (SD)
Coronarography after MPS 4 (4%) 19 (21%) 23 (25%)
Coronarography result    
Normal 2 (2%) 1 (1%) 3 (3%)
Abnormal 2 (2%) 18 (20%) 20 (22%)
Drugs 11 (12%) 65 (71%) 76 (83%)
Drugs group    
ACE inhibitors 4 (3%) 18 (14%) 22 (17%)
Beta-blockers 10 (8%) 40 (31%) 50 (39%)
Nitrates 9 (7%) 49 (38%) 48 (45%)
Symptoms 9 (10%) 48 (53%) 57 (63%)
Type of symptoms    
typical ischaemic 6 (7%) 37 (40%) 43 (47%)
Atypical 3 (3%) 11 (12%) 14 (15%)
Events in observation    
Infarct 0 3 (3%) 3 (3%)
Interventional treatement 2 (2%) 12 (13%) 14 (15%)
Instable coronary disease 0 7 (8%) 7 (8%)
Death 0 10 (11%) 10 (11%)
Figure 3. Number of patients and number of specific cardiac events in 
the groups with a low, medium and high risk of CAD according to MPS 
results; rev — revascularisation, inf — myocardial infarct, de — death, 
unst — unstable CAD, 100% probability — patients diagnosed with 
CAD
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revascularisation was mainly performed within one year after MPS 
and in the fifth year of the observation period.
The Kaplan-Meier no-event survival curves for the group of 
patients s/p major cardiac events are shown in Figure 4.No major 
cardiac events were recorded in the case of patients with normal 
MPS results as opposed to patients with pathological MPS results. 
The factors that are to a statistically significant extent corre-
lated with the occurrence of any cardiac events in the case of the 
observed patients are shown in Table 4. The greatest statistical 
correlation was observed between sex, MPS results, number of 
the involved segments in MPS, number of ischemic segments in 
MPS (p < 0.001).
Discussion
The initial probability of coronary artery disease can play an im-
portant role when selecting the benchmark diagnostic procedure 
or treatment and also when interpreting diagnostic test results. The 
initial probability can be so high that positive test results will con-
tribute little diagnostic information, and there will be a risk of falsely 
negative results. Therefore patients with a strong initial probability 
of CAD are directly referred for coronary angiography. In the case 
of patients without risk factors, and a low initial probability of CAD, 
negative test results are of little diagnostic value, and there is a risk 
of falsely positive results. The attempts at clinical classification of 
patients suspected of CAD in order to apply appropriate treatment 
are not sufficiently good. The classification into CAD risk groups in-
troduced by Diamond is based on simple data concerning the 
patient’s age, sex and type of complaints [6]. A more complex 
version, suggested by Pryor, takes into consideration other risk 
factors: past coronary episodes, diabetes, hypertension, smoking, 
family history of coronary artery disease. The greater the number 
of risk factors, the greater the probability of CAD [7]. 
In the recent literature, some authors [2, 3, 5] have discussed 
the current role of diagnostic test in assessing the prognosis of 
cardiac events. For a prognostic test to be useful, it must be highly 
specific, it should minimise the number of falsely positive results, 
which are rather frequent when prognostic tests are applied to 
a healthy population, it must be adequately sensitive so that 
negative results exclude the probability of an event to the grea-
test possible extent, it must be non-invasive, not too expensive 
and generally available; it must offer information not obtainable 
based on any other procedures. It should identify a pathological 
process at the initial reversible stage so as to enable applying 
appropriate treatment to prevent any adverse consequences for 
patients. 
Among many procedures, myocardial perfusion scintigraphy 
is widely used for assessing prognosis. To date, Tl-201 MPS 
was the most widely applied method [8–10]. The first reports con-
cerning the assessment of the prognostic value of Tc-99m-MIBI 
MPS date back to 1994 [11, 12]. Brown and Stratmann published 
articles on the usability of Tc-99m-MIBI MPS in assessing prog-
nosis. Brown et al. carried out planar MPS with stress induced 
by physical exercise or dipyridamole in patients suspected of or 
diagnosed with coronary artery disease, and then monitored the 
history of patients with normal results over a post-examination 
period of 10 months on average. They showed that only one pa-
tient out of 234 had myocardial infarct in the observation period. 
Stratmann et al. published a study in which they estimated the 
Figure 4. Survival curves for cardiac events (infarct, death) in the case 
of patients with normal and pathological MPS results
table 4. Factors to a statistically significant extent correlated with any cardiac events in (infarct, death, revascularisation, unstable CAD)
Factors Patients with cardiac events n = 50 Patients without cardiac events n = 165
Final distolic blood pressure** 86 ±13 (SD) 80 ± 13 (SD)
Final heart rate* 120 ±22 (SD) 128 ±22 (SD)
Sex*** 43 M / 7 F 91 M / 74 F
History of infarct* 23 (46%) 35 (21%)
Syptoms* 36 (72%) 89 (54%)
Revascularisation** 19 (38%) 33 (20%)
Positive coronarography** 15 (30%) 25 (15%)
Positive stress test before MPS* 27 (54%) 63 (38%)
Positive MPS*** 47 (94%) 59 (36%)
Number of afected segments in MPS*** 147/450 (33%) 112/1485 (8%)
Number of segments with reversible ischaemia in MPS*** 107/450 (24%) 62/1485 (4%)
Statistical signify: *p < 0.05; **p < 0.01; ***p < 0.001
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value of Tc-99m-MIBI MPS with dipyridamole stress in assessing 
the prognosis of cardiac events (infarct, death) in patients referred 
for the examination on account of stable CAD. 355 patients out of 
534 had pathological MPS results. They showed that pathological 
MPS results (including both a cicatrix and reversible ischemia) are 
associated with a higher probability of cardiac events. Within an ob-
servation period of 13 months, 44 patients died, 14 had an infarct, 
in total 11% of the study population, including 2% of patients with 
normal MPS results and 9% with pathological MPS results. 
Miller et al. presented their experiences related to SPECT 
Tc-99m-MIBI MPS with pharmacological stress in assessing prog-
nosis for patients with recent uncomplicated myocardial infarct 
or unstable CAD prior to their discharge from hospital. Based on 
a year-long observation period it was shown that patients with 
pathological MPS results had much worse prognosis compared 
to those with normal results [13].
In a number of studies it was confirmed that as in Tl-201 
MPS, normal results of Tc-99m-MIBI MPS suggested a low risk 
of cardiac events, while pathological results — a significantly 
greater risk thereof. In the case of normal results, the average 
number of events per year is about 1% or less, while in the case 
of pathological results — about 3-10%. Also the data obtained in 
the course of this study support this conclusion. 109 patients with 
normal MPS results had no major cardiac events in the observation 
period, while 17 major cardiac events (5 myocardial infarcts and 
12 cardiac deaths) occurred in the group of 106 patients with 
pathological MPS results, i.e. 4% on average per year. This study 
has an important advantage over the previous works on account 
of a very long observation period of 52 months on average and 
86 months at maximum. Even with such long observation period, 
no events were observed in the case of patients with initially nor-
mal MPS results, although it could have been assumed that CAD 
would progress.
It was shown [14–16] that normal MPS results, despite the sig-
nificant stenosis determined in coronary angiography, are related 
to a very good prognosis. It could suggest that MPS gives a better 
overall functional assessment of myocardial blood supply com-
pared to coronary angiography. In the study of Brown et al., only 
one patient had a major cardiac event, and 2 patients underwent 
revascularisation in the observation period (CABG and PTCA) 
within 8 and 10 months after MPS due to recurring coronary com-
plaints out of 47 patients with normal MPS results and clinically 
significant stenosis (> 50% of the vessel diameter) as determined 
in coronary angiography, including stenosis of coronary vessels in 
30 patients. The annual incidence of cardiac events in the group of 
patients with normal MPS results was < 1%. The disadvantage of 
the study referred to above is a relatively short observation period 
and the application of planar MPS. These disadvantages were 
eliminated by Soman et al., who observed 21 patients with normal 
coronary angiography results and Tc-99m-MIBI SPECT MPS (on 
average) for 30 months; one death and 5 cases of revascularisa-
tion were reported in this period [16]. This study was based on 
SPECT procedure, and the observation period was to a significant 
extent longer compared to that applied in the above-mentioned 
studies. 7 patients with clinically significant stenosis as determined 
in coronary angiography had normal MPS results; in a relatively 
long observation period of more than 52 months, no major cardiac 
events occurred; and 2 patients underwent revascularisation.
The meta-analysis carried out by Iskander et al. [17] which in-
cluded a total of 12 360 patients, both males and females, with sta-
ble CAD showed that patients with pathological MPS results carry 
the risk of cardiac events at 7.4% per year which corresponds to 
the obtained results. In accordance with the world medical literature 
it was shown that the risk of cardiac events grows in proportion 
to the area of impaired perfusion. Amanullah pointed out that the 
assessment of the vascular regions where perfusion is impaired 
contributes to the prognostic value of MPS [18] which is substan-
tially compatible with our results. 
As any other study, also this one is subject to some limitations. 
One of them is the small number of patients in each study group. 
But at the same time these are diverse groups, created based on 
day-to-day clinical practice, with patients who underwent SPECT 
MPS and were analysed according to normal and pathological 
MPS results . A number of patients with pathological results un-
derwent no revascularisation or even coronary angiography, thus it 
can be considered an assessment of the natural course of the 
disease. Kamianek et al. suggested that it would be useful to 
include an additional parameter, such as pulmonary uptake [19]. 
No such parameters were analysed in this study. The currently used 
diagnostic standard in most centres is SPECT-based ECG-gated 
MPS (GatedSPECT) as it enables assessing the ejection fraction 
of the left ventricle and segmental disorders of myocardial con-
tractility. The knowledge of these data increases the sensitivity 
and specificity of the method, and thus the prognostic value of 
the examination [20]. At the time of the study commencement, 
our centre had no GSPECT equipment.
Numerous authors confirmed the strong prognostic value of 
MPS, however, a significant majority of the available studies were 
related to populations of both females and males, frequently with 
a higher percentage of males in the study groups. The studies de-
signed and conducted selectively on a female population suggest 
a higher prognostic value of myocardial perfusion scintigraphy, 
however, they are much less numerous and still under investiga-
tion [21, 22]. The problem of sex-dependent prognostic value of 
MPS is of interest to the authors of this paper, however, it would 
require a separate study due to its scope.
Conclusions
1. Normal results of myocardial perfusion scintigraphy performed 
under stress induced with physical exercise and dipyridamole 
in a group of patients suspected of or diagnosed with coronary 
artery disease: s/p myocardial infarct and/or CABG, contribute 
to the prognosis of a mild course of the disease without or 
with a minimal number of cardiac events, also within a longer 
observation period. 
2. Pathological MPS results clearly imply a greater risk of cardiac 
events; at the same time the number of events increases with 
the greater probability of CAD and with the patient’s age. 
3. Normal MPS results, even with significant changes determined 
in coronary angiography (coronary stenosis), imply a very low 
risk of cardiac events. 
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